Enantiomeric Agonists of the Type 2 Cannabinoid Receptor Reduce Retinal Damage during Proliferative Vitreoretinopathy and Inhibit Hyperactive Microglia <i>In Vitro</i>A. P. Young, Eileen M. Denovan‐Wright|ACS Pharmacology & Translational Science|2024Cited by 5